FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Lucas Svetlana
(Last) (First) (Middle)
C/O SCRIBE THERAPEUTICS INC.
1150 MARINA VILLAGE PARKWAY
(Street)
ALAMEDA CA 94501
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/23/2026 		3. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 30,695
D
 
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 06/16/2029 Common Stock 34,490 2.85 D  
Stock Option (Right to Buy)   (1) 06/07/2030 Common Stock 13,016 3.08 D  
Stock Option (Right to Buy)   (2) 08/05/2031 Common Stock 21,108 6.4 D  
Stock Option (Right to Buy)   (3) 03/20/2035 Common Stock 13,171 6.4 D  
Stock Option (Right to Buy)   (2) 03/12/2036 Common Stock 9,547 19.13 D  
Explanation of Responses:
1. The option, from which certain shares have been previously exercised, is fully vested.
2. The option is fully vested.
3. The options vested as to 25% of the award on January 1, 2026, and the remaining 75% of the option will vest in equal monthly installments thereafter until such time as the options are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ David L. Parrot, Attorney-in-Fact 07/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

ex24-07242026_010758.htm